File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: HMGCo-A reductase inhibitors increase bone formation

TitleHMGCo-A reductase inhibitors increase bone formation
Authors
KeywordsMedical sciences
Dentistry
Issue Date2007
PublisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201925
Citation
The 85th General Session & Exhibition of the IADR, 36th Annual Meeting of the AADR and 31st Annual Meeting of the CADR, New Orleans, LA., 21-24 March 2007. In Journal of Dental Research, 2007, v. 86 spec. iss. A, abstract no. 2541 How to Cite?
AbstractStatin, a HMG-CoA reductase inhibitor, was shown to turn on the gene for bone formation, by blocking the mevalonate pathway in cholesterol production. Naringin is a flavonoid available commonly in citrus fruits which is also a HMG-CoA reductase inhibitor. Objective: To compare the amount of new bone produced by HMG-CoA reductase inhibitors, statin and naringin, in collagen matrix carrier to that of collagen matrix carrier alone. Methods: Twenty bone defects were created in the parietal bone of 12 New Zealand White rabbits. In the experimental groups, 5 defects were grafted with statin solution mixed with collagen matrix carrier, 5 defects were grafted with naringin solution mixed with collagen matrix carrier. In the control groups, 5 defects were grafted with collagen matrix carrier alone (positive control) and 5 were left empty (negative control). Animals were killed on day 14 and the defects were dissected and prepared for histological assessment. Serial sections were cut across each defect. Quantitative analysis of new bone formation was made on 150 sections (50 sections for each group) using image analysis. Results: A total of 308% and 490% more new bone was present in defects grafted with statin in collagen matrix carrier, naringin in collagen matrix carrier, respectively, than those grafted with collagen matrix carrier. No bone was formed in the passive control group. Conclusions: HMGCo-A Reductase Inhibitors like statin and naringin in collagen matrix carriers have the effect of increasing new bone formation locally and can be used as bone graft materials. This has tremendous potential as statin is a commonly prescribed cholesterol-lowering drug whereas naringin is available commonly in edible fruits.
DescriptionSeq #265: Senior - Basic Science Category
Persistent Identifierhttp://hdl.handle.net/10722/94488
ISSN
2015 Impact Factor: 4.602
2015 SCImago Journal Rankings: 1.714

 

DC FieldValueLanguage
dc.contributor.authorWong, RWKen_HK
dc.contributor.authorRabie, ABM-
dc.date.accessioned2010-09-25T15:32:52Z-
dc.date.available2010-09-25T15:32:52Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 85th General Session & Exhibition of the IADR, 36th Annual Meeting of the AADR and 31st Annual Meeting of the CADR, New Orleans, LA., 21-24 March 2007. In Journal of Dental Research, 2007, v. 86 spec. iss. A, abstract no. 2541-
dc.identifier.issn0022-0345-
dc.identifier.urihttp://hdl.handle.net/10722/94488-
dc.descriptionSeq #265: Senior - Basic Science Category-
dc.description.abstractStatin, a HMG-CoA reductase inhibitor, was shown to turn on the gene for bone formation, by blocking the mevalonate pathway in cholesterol production. Naringin is a flavonoid available commonly in citrus fruits which is also a HMG-CoA reductase inhibitor. Objective: To compare the amount of new bone produced by HMG-CoA reductase inhibitors, statin and naringin, in collagen matrix carrier to that of collagen matrix carrier alone. Methods: Twenty bone defects were created in the parietal bone of 12 New Zealand White rabbits. In the experimental groups, 5 defects were grafted with statin solution mixed with collagen matrix carrier, 5 defects were grafted with naringin solution mixed with collagen matrix carrier. In the control groups, 5 defects were grafted with collagen matrix carrier alone (positive control) and 5 were left empty (negative control). Animals were killed on day 14 and the defects were dissected and prepared for histological assessment. Serial sections were cut across each defect. Quantitative analysis of new bone formation was made on 150 sections (50 sections for each group) using image analysis. Results: A total of 308% and 490% more new bone was present in defects grafted with statin in collagen matrix carrier, naringin in collagen matrix carrier, respectively, than those grafted with collagen matrix carrier. No bone was formed in the passive control group. Conclusions: HMGCo-A Reductase Inhibitors like statin and naringin in collagen matrix carriers have the effect of increasing new bone formation locally and can be used as bone graft materials. This has tremendous potential as statin is a commonly prescribed cholesterol-lowering drug whereas naringin is available commonly in edible fruits.-
dc.languageengen_HK
dc.publisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201925-
dc.relation.ispartofJournal of Dental Researchen_HK
dc.rightsJournal of Dental Research. Copyright © Sage Publications, Inc..-
dc.subjectMedical sciences-
dc.subjectDentistry-
dc.titleHMGCo-A reductase inhibitors increase bone formationen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-0345&volume=86&issue=Spec. Iss A&spage=&epage=&date=2007&atitle=HMGCo-A+reductase+inhibitors+increase+bone+formation-
dc.identifier.emailWong, RWK: fyoung@hkucc.hku.hken_HK
dc.identifier.emailRabie, ABM: rabie@hku.hk-
dc.identifier.authorityWong, RWK=rp00038en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros126734en_HK
dc.identifier.volume86-
dc.identifier.issuespec. iss. A-
dc.description.otherThe 85th General Session & Exhibition of the IADR, 36th Annual Meeting of the AADR and 31st Annual Meeting of the CADR, New Orleans, LA., 21-24 March 2007. In Journal of Dental Research, 2007, v. 86 spec. iss. A, abstract no. 2541-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats